SCHEMBL6497984

SCHEMBL6497984

CC(C)(C)[C@](CN)(NS(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 4/20 0.43
ATM Q13315 2/20 0.43
BCAT1 P54687 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
HSD11B1 P28845 1/20 0.41
LARS1 Q9P2J5 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
GLA P06280 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TBXA2R P21731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7415883 0.88 ALDH1A1 (0.46) ALDH1A1CA1CA2MMP1MMP2
SCHEMBL7415885 0.84 SLC1A3 (0.46) ALDH1A1CA1CA2KDM4E
SCHEMBL8648589 0.81 CYP2C19 (0.45) CYP2C19ALDH1A1ATMBCAT1CA1
SCHEMBL8648590 0.81 CYP2C19 (0.45) CYP2C19ALDH1A1ATMBCAT1CA1
SCHEMBL11032086 0.77 ALDH1A1 (0.56) CYP2C19ALDH1A1ATMCA1CA2
SCHEMBL7124462 0.76 GAA (0.45) CYP2C19ALDH1A1CA1CA2MMP2
SCHEMBL10402270 0.75 BCAT1 (0.50) CYP2C19ALDH1A1ATMBCAT1CA1
SCHEMBL14676221 0.72 ATM (0.44) CYP2C19ALDH1A1ATMBCAT1CA1
SCHEMBL28400732 0.72 ALDH1A1 (0.50) CYP2C19ALDH1A1ATMBCAT1CA1
SCHEMBL382267 0.71 ALDH1A1 (0.42) ALDH1A1MMP1MMP13MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059669-A1 M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity AJITO KEIICHI (JP) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059669-A1 M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity ITGAV, ITGB3, ITGA4 CYP2C19 4337/4885ALDH1A1 1967/4885ATM 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.